Aurinia Pharmaceuticals Inc. (AUPH)

5.04 -0.06 (-1.18%) At close: 04:00PM EDT

Aurinia Pharmaceuticals Inc.

118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 300

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Peter S. Greenleaf M.B.A.	President, CEO & Director	1.34M	N/A	1970
Mr. Joseph M. Miller CPA	Chief Financial Officer	791.92k	N/A	1974
Mr. Matthew Maxwell Donley M.B.A.	Executive Vice President of Operations & Strategy	811.82k	N/A	1969
Mr. Stephen P. Robertson	Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer	739.68k	N/A	1982
Dr. Volker Knappertz D.Sc., M.D.	Executive Vice President of Research & Development	742.85k	N/A	1965
Andrea Levin Christopher	Head of the Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Fran Lynch	Vice President of Sales	N/A	N/A	N/A
Mr. Michael R. Martin	Chief Business Officer	350.57k	N/A	1972
Ms. Sue Evans	Senior Vice President of Global Regulatory Affairs	N/A	N/A	N/A
Mr. Scott Habig	Chief Commercial Officer	N/A	N/A	1960

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Corporate governance

Aurinia Pharmaceuticals Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.